Instruction for use: Prosterid

Active substance:

Finasteride

ATX code

G04CB01 Finasteride

Pharmacological group

5-alpha-reductase inhibitor [Androgens, antiandrogens]

5-alpha-reductase inhibitor [Medications that affect the metabolism of the prostate gland and correctors of urodynamics]

Nosological classification (ICD-10)

N40 Prostatic hyperplasia

Prostate adenoma, BPH, Hypertrophy of the prostate, Hypertrophy of the prostate, Dysuric disorders due to benign prostatic hyperplasia, Dysuria with prostatic adenoma, Benign prostatic hyperplasia, Benign prostatic hyperplasia of stage 1 and 2, Benign prostatic hyperplasia of the first degree, Benign prostatic hyperplasia of II degree, Benign prostatic hypertrophy, Disease of the prostate, Acute urinary retention associated with benign prostatic hyperplasia, Benign prostatic hyperplasia 1 and 2 stages in combination with prostatitis, The paradoxical ishuria

R33 Retention of urine

The paradoxical ishuria, Acute urinary retention associated with benign prostatic hyperplasia

R39.1 Other difficulties with micturition

Frequent urination, urinary retention, strangury, Obstructed flow of urine, Violation of urination, Violation of urination, Violation of bladder emptying, Violation of the outflow of urine, Frequent urination, Abnormalities of urination

Composition

Tablets, coated with a film membrane 1 tab.

active substance:

Finasteride 5 mg

Excipients

Core: magnesium stearate - 0.75 mg; Talcum - 4,5 mg; Sodium carboxymethyl starch (type A) 7.5 mg; Pregelatinized starch - 15 mg; MCC - 15 mg; Lactose monohydrate 102.25 mg

Film coating: titanium dioxide (CI 77891 EEC 171) - 0.1881 mg; Lactose monohydrate 0.3809 mg; Macrogol 6000 - 0.6214 mg; Hydroxypropylcellulose - 1.9048 mg; Hypromellose - 1.9048 mg

pharmachologic effect

Pharmacological action - antiandrogenic.

Dosing and Administration

Inside.

Designed exclusively for men.

The usual daily dose: 1 table. (5 mg) for at least 6 months.

Elderly: a change in dose is not required, despite the delayed excretion from the body (about 8 hours).

Renal failure: dose reduction is not required, because Excretion is carried out mainly with feces; The basic kinetic parameters (T1 / 2, Cmax, AUC) are similar to those of healthy people.

Form of issue

Tablets, film-coated, 5 mg. In a blister of aluminum / PVC for 14 pcs. 1 or 2 blisters in a cardboard box.

Terms of leave from pharmacies

On prescription.

Storage conditions

In the dark place at a temperature of 15-30 ° C.

Keep out of the reach of children.

Shelf life

3 years.

Do not use after the expiry date printed on the package.